Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Inflammopharmacology ; 32(2): 1545-1573, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38308793

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is a prominent cause of dementia, resulting in neurodegeneration and memory impairment. This condition imposes a considerable public health burden on both patients and their families due to the patients' functional impairments as well as the psychological and financial constraints. It has been well demonstrated that its aetiology involves proteinopathy, mitochondriopathies, and enhanced reactive oxygen species (ROS) generation, which are some of the key features of AD brains that further result in oxidative stress, excitotoxicity, autophagy, and mitochondrial dysfunction. OBJECTIVE: The current investigation was created with the aim of elucidating the neurological defence mechanism of trans,trans-Farnesol (TF) against intracerebroventricular-streptozotocin (ICV-STZ)-induced Alzheimer-like symptoms and related pathologies in rodents. MATERIALS AND METHODS: The current investigation involved male SD rats receiving TF (25-100 mg/kg, per oral) consecutively for 21 days in ICV-STZ-treated animals. An in silico study was carried out to explore the possible interaction between TF and NADH dehydrogenase and succinate dehydrogenase. Further, various behavioural (Morris water maze and novel object recognition test), biochemical (oxidants and anti-oxidant markers), activities of mitochondrial enzyme complexes and acetylcholinesterase (AChE), pro-inflammatory (tumor necrosis factor-alpha; TNF-α) levels, and histopathological studies were evaluated in specific brain regions. RESULTS: Rats administered ICV-STZ followed by treatment with TF (25, 50, and 100 mg/kg) for 21 days had significantly better mental performance (reduced escape latency to access platform, extended time spent in target quadrant, and improved differential index) in the Morris water maze test and new object recognition test models when compared to control (ICV-STZ)-treated groups. Further, TF treatment significantly restored redox proportion, anti-oxidant levels, regained mitochondrial capacities, attenuated altered AChE action, levels of TNF-α, and histopathological alterations in certain brain regions in comparison with control. In in silico analysis, TF caused greater interaction with NADH dehydrogenase and succinate dehydrogenase. CONCLUSION: The current work demonstrates the neuroprotective ability of TF in an experimental model with AD-like pathologies. The study further suggests that the neuroprotective impacts of TF may be related to its effects on TNF-α levels, oxidative stress pathways, and mitochondrial complex capabilities.


Subject(s)
Alzheimer Disease , Neuroprotective Agents , Rats , Male , Humans , Animals , Alzheimer Disease/chemically induced , Alzheimer Disease/drug therapy , Farnesol/adverse effects , Streptozocin/pharmacology , Succinate Dehydrogenase/metabolism , Succinate Dehydrogenase/pharmacology , Antioxidants/metabolism , Rats, Wistar , Acetylcholinesterase/metabolism , Tumor Necrosis Factor-alpha/metabolism , NADH Dehydrogenase/metabolism , NADH Dehydrogenase/pharmacology , NADH Dehydrogenase/therapeutic use , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Rats, Sprague-Dawley , Oxidative Stress , Maze Learning , Disease Models, Animal
2.
Inflammopharmacology ; 31(6): 2955-2971, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37843641

ABSTRACT

Traumatic brain injury (TBI) is a type of brain injury resulting from a sudden physical force to the head. TBI can range from mild, such as a concussion, to severe, which might result in long-term complications or even death. The initial impact or primary injury to the brain is followed by neuroinflammation, excitotoxicity, and oxidative stress, which are the hallmarks of the secondary injury phase, that can further damage the brain tissue. Dexamethasone (DXM) has neuroprotective effects. It reduces neuroinflammation, a critical factor in secondary injury-associated neuronal damage. DXM can also suppress the microglia activation and infiltrated macrophages, which are responsible for producing pro-inflammatory cytokines that contribute to neuroinflammation. Considering the outcomes of this research, some of the effects of DXM on TBI include: (1) DXM-loaded hydrogels reduce apoptosis, neuroinflammation, and lesion volume and improves neuronal cell survival and motor performance, (2) DXM treatment elevates the levels of Ndufs2, Gria3, MAOB, and Ndufv2 in the hippocampus following TBI, (3) DXM decreases the quantity of circulating endothelial progenitor cells, (4) DXM reduces the expression of IL1, (5) DXM suppresses the infiltration of RhoA + cells into primary lesions of TBI and (6) DXM treatment led to an increase in fractional anisotropy values and a decrease in apparent diffusion coefficient values, indicating improved white matter integrity. According to the study, the findings show that DXM treatment has neuroprotective effects in TBI. This indicates that DXM is a promising therapeutic approach to treating TBI.


Subject(s)
Brain Injuries, Traumatic , Neuroprotective Agents , Animals , Mice , Neuroinflammatory Diseases , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Brain Injuries, Traumatic/drug therapy , Inflammation/metabolism , Dexamethasone/pharmacology , Disease Models, Animal , Microglia , Mice, Inbred C57BL , NADH Dehydrogenase/metabolism , NADH Dehydrogenase/pharmacology , NADH Dehydrogenase/therapeutic use
3.
J Acupunct Meridian Stud ; 16(2): 49-55, 2023 Apr 30.
Article in English | MEDLINE | ID: mdl-37076179

ABSTRACT

Background: A significant amount of research has been conducted to establish the validity of acupuncture, and it has been demonstrated through animal disease model studies that acupuncture influences mitochondrial changes. However, to more accurately examine the mechanisms of acupuncture treatment effectiveness in pathological models, it is crucial to investigate changes in disease-free animals. Among various hypotheses regarding the effects of acupuncture on the body, we focused on the result that acupuncture stimulation is related to mitochondria. Objectives: We examined the effects of acupuncture mitochondrial fission and fusionrelated mediators in disease-free Sprague Dawley (SD) rats' spleen meridian acupoints. Methods: SD rats were divided into control, SP1, SP2, SP3, SP5, and SP9 acupuncture groups. Acupuncture was performed at each point for 10 minutes daily for four days. Peroxisome proliferator-activated receptor-gamma coactivator 1-α (PGC-1α) and fission protein 1 (Fis1) levels were evaluated using quantitative real-time polymerase chain reaction (qRT-PCR), while dynamin-related protein 1 (DRP1), optic atrophy-1 (OPA1), mitofusin-1 (MFN1), and mitofusin-2 (MFN2) levels were assessed via western blotting. Mitochondria protein concentrations and NADH dehydrogenase activity in spleen tissues were measured using enzyme-linked immunosorbent assay (ELISA). Results: PGC-1α expression decreased in the SP1 (p < 0.01), SP5 (p < 0.05), and SP9 (p < 0.05) groups, while Fis1 expression increased in the SP1 (p < 0.01), SP5 (p < 0.01), and SP9 (p < 0.05) groups. DRP1, OPA1, MFN1, and MFN2 levels exhibited no significant changes. Mitochondrial protein concentrations decreased in the SP2 (p < 0.01), SP3 (p < 0.01), SP5 (p < 0.01), and SP9 (p < 0.01) groups, while NADH dehydrogenase activity decreased in the SP2 (p < 0.05) and SP9 (p < 0.05) groups. Conclusion: Acupuncture at the SP9 acupoint influenced the mitochondrial fission pathway by modulating PGC-1α and Fis1 mediators in the rat spleen under non-disease conditions.


Subject(s)
Acupuncture Therapy , Mitochondrial Dynamics , Rats , Animals , Rats, Sprague-Dawley , Mitochondrial Dynamics/physiology , NADH Dehydrogenase/pharmacology , Spleen , Gene Expression
4.
Int Heart J ; 63(5): 970-977, 2022 Sep 30.
Article in English | MEDLINE | ID: mdl-36104228

ABSTRACT

Hypertrophic cardiomyopathy is a common cardiac complication in mitochondrial disorders, and the morbidity rate in neonatal cases is up to 40%. The mortality rate within 3 months for neonatal-onset mitochondrial cardiomyopathy is known to be high because there is currently no established treatment.We report the case of a male infant with neonatal-onset mitochondrial disorder presenting lactic acidosis and hypertrophic cardiomyopathy. Genetic analysis of the patient revealed recurrent m.13513G>A, p.Asp393Asn in mitochondrially encoded NADH dehydrogenase 5 gene (MT-ND5). Low-dose propranolol was initially administered for cardiomyopathy; however, he developed hypertrophic obstructive cardiomyopathy (HOCM) at 3 months of age. To reduce the risk of hypoglycemia associated with high-dose propranolol, cibenzoline, a class Ia antiarrhythmic drug, was added at a dose of 2.5 mg/kg/day and increased weekly to 7.5 mg/kg/day with monitoring of the blood concentration of cibenzoline. Left ventricular outflow tract stenosis (LVOTS) dramatically improved from 5.4 to 1.3 m/second in LVOTS peak velocity after 6 weeks, without notable adverse effects. The plasma N-terminal pro-brain natriuretic peptide level decreased from 65,854 to 10,044 pg/mL. Furthermore, myocardial hypertrophy also improved, as the left ventricular mass index decreased from 173.1 to 108.9 g/m2 after 3 months of the treatment.The administration of cibenzoline, in conjunction with low-dose propranolol, may serve an effective treatment for HOCM in infantile patients with mitochondrial disorders.


Subject(s)
Anti-Arrhythmia Agents , Cardiomyopathy, Hypertrophic , Anti-Arrhythmia Agents/therapeutic use , Cardiomyopathy, Hypertrophic/complications , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/drug therapy , Constriction, Pathologic , Humans , Imidazoles , Infant, Newborn , Male , NADH Dehydrogenase/pharmacology , NADH Dehydrogenase/therapeutic use , Propranolol/pharmacology , Propranolol/therapeutic use , Ventricular Function, Left
5.
J Immunol ; 195(8): 4020-7, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26378078

ABSTRACT

Mitochondria provide energy for cells via oxidative phosphorylation. Reactive oxygen species, a byproduct of this mitochondrial respiration, can damage mitochondrial DNA (mtDNA), and somatic mtDNA mutations have been found in all colorectal, ovarian, breast, urinary bladder, kidney, lung, and pancreatic tumors studied. The resulting altered mitochondrial proteins or tumor-associated mitochondrial Ags (TAMAs) are potentially immunogenic, suggesting that they may be targetable Ags for cancer immunotherapy. In this article, we show that the RENCA tumor cell line harbors TAMAs that can drive an antitumor immune response. We generated a cellular tumor vaccine by pulsing dendritic cells with enriched mitochondrial proteins from RENCA cells. Our dendritic cell-based RENCA mitochondrial lysate vaccine elicited a cytotoxic T cell response in vivo and conferred durable protection against challenge with RENCA cells when used in a prophylactic or therapeutic setting. By sequencing mtDNA from RENCA cells, we identified two mutated molecules: COX1 and ND5. Peptide vaccines generated from mitochondrial-encoded COX1 but not from ND5 had therapeutic properties similar to RENCA mitochondrial protein preparation. Thus, TAMAs can elicit effective antitumor immune responses, potentially providing a new immunotherapeutic strategy to treat cancer.


Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Carcinoma, Renal Cell/prevention & control , Cyclooxygenase 1/immunology , Kidney Neoplasms/prevention & control , Membrane Proteins/immunology , Mitochondrial Proteins/immunology , NADH Dehydrogenase/immunology , Neoplasms, Experimental/prevention & control , Animals , Antigens, Neoplasm/pharmacology , Cancer Vaccines/pharmacology , Carcinoma, Renal Cell/immunology , Cyclooxygenase 1/pharmacology , Kidney Neoplasms/immunology , Membrane Proteins/pharmacology , Mice , Mice, Inbred BALB C , Mitochondrial Proteins/pharmacology , NADH Dehydrogenase/pharmacology , Neoplasms, Experimental/immunology
6.
Nat Neurosci ; 14(10): 1260-6, 2011 Sep 04.
Article in English | MEDLINE | ID: mdl-21892157

ABSTRACT

Mice heterozygous for the homeobox gene Engrailed-1 (En1) display progressive loss of mesencephalic dopaminergic (mDA) neurons. We report that exogenous Engrailed-1 and Engrailed-2 (collectively Engrailed) protect mDA neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a mitochondrial complex I toxin used to model Parkinson's disease in animals. Engrailed enhances the translation of nuclearly encoded mRNAs for two key complex I subunits, Ndufs1 and Ndufs3, and increases complex I activity. Accordingly, in vivo protection against MPTP by Engrailed is antagonized by Ndufs1 small interfering RNA. An association between Engrailed and complex I is further confirmed by the reduced expression of Ndufs1 and Ndufs3 in the substantia nigra pars compacta of En1 heterozygous mice. Engrailed also confers in vivo protection against 6-hydroxydopamine and α-synuclein-A30P. Finally, the unilateral infusion of Engrailed into the midbrain increases striatal dopamine content, resulting in contralateral amphetamine-induced turning. Therefore, Engrailed is both a survival factor for adult mDA neurons and a regulator of their physiological activity.


Subject(s)
Dopamine/metabolism , Homeodomain Proteins/metabolism , Mesencephalon/cytology , Nerve Tissue Proteins/metabolism , Neurons/physiology , Neurotoxins/toxicity , Animals , Cell Count/methods , Cells, Cultured , Chromatography, High Pressure Liquid/methods , Dizocilpine Maleate/pharmacology , Dopamine Plasma Membrane Transport Proteins/metabolism , Electron Transport Chain Complex Proteins/metabolism , Embryo, Mammalian , Homeodomain Proteins/pharmacology , In Vitro Techniques , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , NADH Dehydrogenase/pharmacology , Nerve Tissue Proteins/pharmacology , Neurons/drug effects , Nitro Compounds/toxicity , Oxidopamine/toxicity , Propionates/toxicity , RNA, Small Interfering/pharmacology , Rotenone/toxicity , Stereotyped Behavior/drug effects , Tyrosine 3-Monooxygenase/metabolism , alpha-Synuclein/metabolism
7.
Nitric Oxide ; 21(2): 132-9, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19576290

ABSTRACT

Mitochondria recently have emerged as important sites in controlling NO levels within the cell. In this study, the synthesis of nitric oxide (NO) from nitrite and its degradation by mitochondria isolated from Arabidopsis thaliana were examined. Oxygen and NO concentrations in the reaction medium were measured with specific electrodes. Nitrite inhibited the respiration of isolated A. thaliana mitochondria, in competition with oxygen, an effect that was abolished or potentiated when electron flow occurred via alternative oxidase (AOX) or cytochrome c oxidase (COX), respectively. The production of NO from nitrite was detected electrochemically only under anaerobiosis because of a superoxide-dependent process of NO degradation. Electron leakage from external NAD(P)H dehydrogenases contributed the most to NO degradation as higher rates of Amplex Red-detected H(2)O(2) production and NO consumption were observed in NAD(P)H-energized mitochondria. Conversely, the NO-insensitive AOX diminished electron leakage from the respiratory chain, allowing the increase of NO half-life without interrupting oxygen consumption. These results show that the accumulation of nitric oxide derived from nitrite reduction and the superoxide-dependent mechanism of NO degradation in isolated A. thaliana mitochondria are influenced by the external NAD(P)H dehydrogenases and AOX, revealing a role for these alternative proteins of the mitochondrial respiratory chain in the control of NO levels in plant cells.


Subject(s)
Arabidopsis/metabolism , Electron Transport Complex III/metabolism , Mitochondria/metabolism , NADH Dehydrogenase/metabolism , Nitric Oxide/metabolism , Nitrites/metabolism , Superoxides/metabolism , Arabidopsis Proteins/metabolism , Data Interpretation, Statistical , Electron Transport Complex IV/metabolism , Mitochondrial Proteins , NAD/metabolism , NADH Dehydrogenase/pharmacology , Oxidoreductases/metabolism , Oxygen/metabolism , Plant Proteins
8.
Analyst ; 134(2): 349-53, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19173061

ABSTRACT

The use of the alkaline phosphatase (AP) as an enzyme label and the amplification of its analytical response with a diaphorase (DI) secondary enzyme were investigated in an electrochemical hybridization assay involving arrays of carbon screen-printed DNA biosensors for the sensitive quantification of an amplified 406-base pair human cytomegalovirus DNA sequence (HCMV DNA). For this purpose, PCR-amplified biotinylated HCMV DNA targets were simultaneously bound to a monolayer of neutravidin irreversibly adsorbed on the surface of the electrodes and hybridized to complementary digoxigenin-labeled detection probes. The amount of hybrids immobilized on the electrode surface was labeled with an anti-digoxigenin AP conjugate and quantified electrochemically by measuring the activity of the AP label through the hydrolysis of the electroinactive p-aminophenylphosphate (PAPP) substrate into the p-aminophenol (PAP) product. The intensity of the cyclic voltammetric anodic peak current resulting from the oxidation of PAP into p-quinoneimine (PQI) was related to the number of viral amplified DNA targets present in the sample, and a detection limit of 10 pM was thus achieved. The electrochemical response of the AP label product was further enhanced by adding the diaphorase enzymatic amplifier in the solution. In the presence of the auxiliary enzyme DI, the PQI was reduced back to PAP and the resulting oxidized form of DI was finally regenerated in its reduced native state by its natural substrate, NADH. Such a bienzymatic amplification scheme enabled a 100-fold lowering of the HCMV DNA detection limit obtained with the monoenzymatic system.


Subject(s)
Biosensing Techniques/methods , Nucleic Acid Amplification Techniques , Alkaline Phosphatase/pharmacology , Cytomegalovirus/genetics , DNA, Viral/analysis , Electrochemistry/methods , Humans , NADH Dehydrogenase/pharmacology , Oligonucleotide Array Sequence Analysis
9.
J Neurochem ; 100(6): 1469-79, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17241123

ABSTRACT

Parkinson's disease (PD) has been linked to mitochondrial dysfunction and pesticide exposure. The pesticide rotenone (ROT) inhibits complex I and reproduces features of PD in animal models, suggesting that environmental agents that inhibit complex I may contribute to PD. We have previously demonstrated that ROT toxicity is dependent upon complex I inhibition and that oxidative stress is the primary mechanism of toxicity. In this study, we examined the in vitro toxicity and mechanism of action of several putative complex I inhibitors that are commonly used as pesticides. The rank order of toxicity of pesticides to neuroblastoma cells was pyridaben > rotenone > fenpyroximate > fenazaquin > tebunfenpyrad. A similar order of potency was observed for reduction of ATP levels and competition for (3)H-dihydrorotenone (DHR) binding to complex I, with the exception of pyridaben (PYR). Neuroblastoma cells stably expressing the ROT-insensitive NADH dehydrogenase of Saccharomyces cerevisiae (NDI1) were resistant to these pesticides, demonstrating the requirement of complex I inhibition for toxicity. We further found that PYR was a more potent inhibitor of mitochondrial respiration and caused more oxidative damage than ROT. The oxidative damage could be attenuated by NDI1 or by the antioxidants alpha-tocopherol and coenzyme Q(10). PYR was also highly toxic to midbrain organotypic slices. These data demonstrate that, in addition to ROT, several commercially used pesticides directly inhibit complex I, cause oxidative damage, and suggest that further study is warranted into environmental agents that inhibit complex I for their potential role in PD.


Subject(s)
Adenosine Triphosphate/metabolism , Electron Transport Complex I/metabolism , Mitochondria/drug effects , Pesticides/toxicity , Animals , Animals, Newborn , Antioxidants/pharmacology , Cell Death/drug effects , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Interactions , Humans , In Vitro Techniques , Male , Mesencephalon/ultrastructure , NADH Dehydrogenase/pharmacology , Neuroblastoma , Pesticides/chemistry , Protein Carbonylation/drug effects , Rats , Rats, Inbred Lew , Rotenone/analogs & derivatives , Rotenone/pharmacokinetics , Saccharomyces cerevisiae Proteins/pharmacology , Tyrosine 3-Monooxygenase/metabolism , alpha-Tocopherol/pharmacology
10.
J Bioenerg Biomembr ; 31(4): 335-45, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10665524

ABSTRACT

This review summarizes recent progress on the regulation of the mitochondrial permeability transition pore, an inner membrane channel that may play a role in cell death. We briefly cover its key control points as emerged over the last few years from studies on isolated mitochondria; and describe in some detail our recent results indicating that the pore is modulated by the respiratory chain complex I and can be specifically blocked by selected ubiquinone analogs. We discuss the potential relevance of these findings for the structural definition of the permeability transition pore and illustrate the pharmacological perspectives they offer in diseases where mitochondrial dysfunction is suspected to play a key role.


Subject(s)
Intracellular Membranes/metabolism , Mitochondria/ultrastructure , Permeability/drug effects , Animals , Humans , Intracellular Membranes/drug effects , Mitochondria/enzymology , NADH Dehydrogenase/metabolism , NADH Dehydrogenase/pharmacology , Ubiquinone/analogs & derivatives , Ubiquinone/pharmacology
11.
J Exp Med ; 171(3): 897-912, 1990 Mar 01.
Article in English | MEDLINE | ID: mdl-2307936

ABSTRACT

Maternally transmitted factor (Mtf) is a mitochondrial gene that controls the antigenic polymorphism of the MHC class I maternally transmitted antigen (Mta). Synthetic peptides from the NH2 terminus of the mitochondrially encoded NADH dehydrogenase subunit 1 (ND1) mimic Mtf peptide activity in an allele-specific manner. We show that the minimal ND1-alpha peptide length recognized by Mtaa-specific polyclonal CTLs was between 8 and 12 amino acids, while some Mtaa-specific CTL clones recognized a six amino acid peptide. The N-formyl group at the NH2 terminus of ND1 was essential for Mta activity. Competition experiments using N-substituted ND1-alpha peptides showed that an N-formyl peptide receptor on the target cell, which differs from the chemotactic peptide receptor, was required for Mta expression. The specificity of this receptor can account for the distinct immune restriction of Mta in which Mtf peptides are uniquely restricted by Hmt. It is possible that the Hmt gene product is the N-formyl peptide receptor itself and that it represents a class I antigen presentation molecule specialized for binding, transport, and immune presentation of N-formyl-peptide antigens of mitochondrial and prokaryotic origin.


Subject(s)
Histocompatibility Antigens Class I/physiology , Receptors, Immunologic/physiology , Animals , Female , Male , Methionine , Mice , Mice, Inbred Strains , Mitochondria/metabolism , NADH Dehydrogenase/genetics , NADH Dehydrogenase/pharmacology , Receptors, Formyl Peptide , Receptors, Immunologic/analysis , Structure-Activity Relationship , T-Lymphocytes, Cytotoxic/immunology
12.
J Pharmacobiodyn ; 4(7): 528-33, 1981 Jul.
Article in English | MEDLINE | ID: mdl-6795335

ABSTRACT

Various kinds of flavoenzymes such as NADPH-cytochrome c reductase, NADH-cytochrome b5 reductase, xanthine oxidase, lipoamide dehydrogenase and NADH dehydrogenase supplemented with their electron donors exhibited the sulfoxide reductase activity in the presence of a partially purified soluble factor from guinea pig liver. The present study suggests that new electron transfer systems in which the soluble factor functions as an electron carrier coupled with flavoenzymes described above are responsible for the sulfoxide reduction.


Subject(s)
Biological Products/pharmacology , Liver/metabolism , Oxidoreductases/pharmacology , Sulfoxides/metabolism , Animals , Cricetinae , Cytochrome Reductases/pharmacology , Cytochrome-B(5) Reductase , Dihydrolipoamide Dehydrogenase/pharmacology , Electron Transport , Guinea Pigs , Mesocricetus , Mice , NADH Dehydrogenase/pharmacology , NADPH-Ferrihemoprotein Reductase/pharmacology , Rabbits , Rats , Xanthine Oxidase/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...